Protagonist Therapeutics Inc (PTGX)

10:34 AM

Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026 - The Oklahoman

10:34 AM

Jan 08, 2026

Can Protagonist Therapeutics Inc. stock rebound after recent weaknessWatch List & AI Driven Stock Reports - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

How Protagonist Therapeutics Inc. stock benefits from strong dollarJuly 2025 Snapshot & Daily Volume Surge Signals - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Will Protagonist Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Chart Watch & Accurate Intraday Trade Tips - ulpravda.ru

Jan 08, 2026

Jan 07, 2026

Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge? - Yahoo Finance

Jan 07, 2026

Jan 06, 2026

Protagonist (PTGX) Stock Pre-Market (-6.4%): NDA Submission For Rusfertide Triggers Sell-The-News - Trefis

Jan 06, 2026

Jan 06, 2026

Protagonist Therapeutics (PTGX) Target Price Raised by Truist Se - GuruFocus

Jan 06, 2026

Jan 05, 2026

Truist raises Protagonist Therapeutics stock price target to $110 on pivotal year ahead - Investing.com Canada

Jan 05, 2026

Jan 04, 2026

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Victorville Daily Press

Jan 04, 2026

Jan 02, 2026

(PTGX) Volatility Zones as Tactical Triggers - Stock Traders Daily

Jan 02, 2026

Jan 01, 2026

Moody Aldrich Partners LLC Sells 27,510 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Jan 01, 2026

Jan 01, 2026

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Galesburg Register Mail

Jan 01, 2026

Dec 31, 2025

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Dec 31, 2025

Dec 28, 2025

Protagonist Therapeutics Earnings Notes - Trefis

Dec 28, 2025

Dec 26, 2025

Protagonist Therapeutics Advances Pipeline Amid Financial Loss - MSN

Dec 26, 2025

Dec 26, 2025

Exchange Traded Concepts LLC Sells 13,839 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Dec 26, 2025

Dec 22, 2025

(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily

Dec 22, 2025

Dec 22, 2025

Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Voya Investment Management LLC - MarketBeat

Dec 22, 2025

Dec 22, 2025

Assenagon Asset Management S.A. Decreases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Dec 22, 2025

Dec 21, 2025

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - Daytona Beach News-Journal

Dec 21, 2025

Dec 21, 2025

Protagonist Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis

Dec 21, 2025

Dec 20, 2025

Aug Selloffs: Why Protagonist Therapeutics Inc stock is recommended by analystsJuly 2025 Pullbacks & Smart Allocation Stock Reports - moha.gov.vn

Dec 20, 2025

Dec 20, 2025

Jefferies Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail

Dec 20, 2025

Dec 19, 2025

Why Protagonist Therapeutics Inc. stock is favored by top institutionsPortfolio Risk Report & Fast Gain Stock Tips - DonanımHaber

Dec 19, 2025

Dec 19, 2025

Is Protagonist Therapeutics Inc. stock a contrarian buyChart Signals & Consistent Income Trade Recommendations - Улправда

Dec 19, 2025

Dec 18, 2025

Why Protagonist Therapeutics Inc. stock is recommended by analysts2025 Volatility Report & Reliable Volume Spike Trade Alerts - Улправда

Dec 18, 2025

Dec 18, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 5.6%Should You Sell? - MarketBeat

Dec 18, 2025

Dec 17, 2025

Barclays Maintains Protagonist Therapeutics (PTGX) Overweight Recommendation - Nasdaq

Dec 17, 2025

Dec 17, 2025

Protagonist Therapeutics (PTGX) Target Price Raised by Barclays - GuruFocus

Dec 17, 2025

Dec 17, 2025

How Investors Are Reacting To Protagonist Therapeutics (PTGX) Rusfertide’s Pivotal Phase 3 VERIFY Results - Sahm

Dec 17, 2025

Dec 16, 2025

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Green Bay Press-Gazette

Dec 16, 2025

Dec 15, 2025

Three Stocks That May Be Undervalued In December 2025 - Sahm

Dec 15, 2025

Dec 14, 2025

Valuing Protagonist Therapeutics (PTGX) After New 52-Week Phase 3 VERIFY Data on Rusfertide - Sahm

Dec 14, 2025

Dec 13, 2025

Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year HighWhat's Next? - MarketBeat

Dec 13, 2025

Dec 13, 2025

Protagonist Therapeutics, Inc. $PTGX Shares Purchased by BVF Inc. IL - MarketBeat

Dec 13, 2025

Dec 13, 2025

683 Capital Management LLC Reduces Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Dec 13, 2025

Dec 13, 2025

Protagonist Therapeutics stock hits all-time high at 93.53 USD By Investing.com - Investing.com Australia

Dec 13, 2025

Dec 12, 2025

Protagonist Therapeutics stock hits all-time high at 93.53 USD - Investing.com India

Dec 12, 2025

Dec 12, 2025

Citizens maintains Protagonist Therapeutics stock rating, citing rusfertide efficacy By Investing.com - Investing.com Canada

Dec 12, 2025

Dec 12, 2025

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $803,000 Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Dec 12, 2025

Dec 12, 2025

Natixis Purchases Shares of 42,040 Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Dec 12, 2025

Dec 11, 2025

VIX Spike: How Protagonist Therapeutics Inc stock benefits from strong dollar2025 Winners & Losers & Fast Entry Momentum Trade Alerts - moha.gov.vn

Dec 11, 2025

Dec 11, 2025

How (PTGX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com

Dec 11, 2025

Dec 11, 2025

HighVista Strategies LLC Lowers Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Dec 11, 2025

Dec 11, 2025

High Growth Tech Stocks In The US Market With Potential - Yahoo Finance

Dec 11, 2025